Washington DC… As consumers shop for health plans during open enrollment, the HIV+Hepatitis Policy Institute is reminding people, particularly those who depend on prescription drugs, to carefully review plan policies regarding copay assistance…
Washington DC…In a setback to patients’ ability to afford prescription drugs, the Trump administration has again attacked the use of drug manufacturer copay assistance for prescription…
Washington DC…Today, in a shock to patients, the Trump administration announced that health insurers do not have to count copay assistance from drug manufacturers towards…
Washington DC… Earlier this week the HIV + Hepatitis Policy Institute submitted comments to the HHS in strong opposition to a proposal that would dramatically increase the cost of prescription drugs for patients…
Washington DC…In response to the release of the draft 2021 Notice of Benefit and Payment Parameters rule by HHS today, Carl Schmid of the HIV + Hepatitis Policy Institute, who has been a leading…